Blueprint Medicines Corp (BPMC)
92.55
+3.49
(+3.92%)
USD |
NASDAQ |
Sep 27, 16:00
92.45
-0.10
(-0.11%)
After-Hours: 20:00
Blueprint Medicines SG&A Expense (Annual): 295.14M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 295.14M |
| December 31, 2022 | 237.37M |
| December 31, 2021 | 195.29M |
| December 31, 2020 | 157.74M |
| December 31, 2019 | 96.39M |
| December 31, 2018 | 47.93M |
| Date | Value |
|---|---|
| December 31, 2017 | 27.99M |
| December 31, 2016 | 19.22M |
| December 31, 2015 | 14.46M |
| December 31, 2014 | 7.89M |
| December 31, 2013 | 5.072M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
96.39M
Minimum
2019
295.14M
Maximum
2023
196.39M
Average
195.29M
Median
2021
SG&A Expense (Annual) Benchmarks
| Viking Therapeutics Inc | 37.02M |
| RxSight Inc | 74.80M |
| Boston Scientific Corp | 5.19B |
| Masimo Corp | 664.00M |
| iRhythm Technologies Inc | 385.64M |